EC Gynaecology

Objective: This study's objective was to evaluate the awareness of Saudi women concerning the indications for the usage of Metformin in managing PCOS. It is the first-line treatment for managing insulin resistance-associated PCOS. Its underutilization stems from a lack of awareness among patients.

Methods: This cross-sectional study included women of reproductive age in Saudi Arabia. Copies of the electronic survey were distributed to the target population. The study was conducted over 2 months, November and December 2024.

Results: The study included 436 participants from Saudi Arabia. 38.8% were 20 - 30 years old. 82.1% recognized the importance of lifestyle changes for lowering insulin levels. While 36% were aware of metformin, 47.9% had not heard of it. 49.7% agreed that metformin might lower the chance of type 2 diabetes in women with PCOS, and 54.3% believed that it could help maintain regular menstrual cycles. Among the participants, 14.9% reported not using metformin, citing forgetfulness, side effects, and financial issues as barriers.

Conclusion: The majority of women had limited knowledge and understanding of this treatment. While most women with PCOS were aware of metformin as a medication, they lacked detailed information about its specific indications and benefits for managing PCOS. Many women did not know that metformin could help regulate menstrual cycles, improve insulin resistance, and potentially assist with weight management, which are key treatment goals for PCOS.

 Keywords: Metformin; Polycystic ovarian syndrome; PCOS; Women; Saudi Arabia

1. Patel S. “Polycystic ovary syndrome (PCOS), an inflammatory, systemic, lifestyle endocrinopathy”. Journal of Steroid Biochemistry and Molecular Biology 182 (2018): 27-36.
2. Liao B., et al. “Central regulation of PCOS: abnormal neuronal-reproductive-metabolic circuits in PCOS pathophysiology”. Frontiers in Endocrinology (Lausanne) 12 (2021): 667422.
3. Christ JP and Cedars MI. “Current guidelines for diagnosing PCOS”. Diagnostics6 (2023): 1113.
4. Smet M-E and McLennan A. “Rotterdam criteria, the end”. Australasian Journal of Ultrasound in Medicine 2 (2018): 59-60.
5. Azziz R., et al. “The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report”. Fertility and Sterility2 (2009): 456-488.
6. Purwar A and Nagpure S. “Insulin resistance in polycystic ovarian syndrome”. Cureus10 (2022): e30351.
7. Szymczak-Pajor I., et al. “Metabolic action of metformin”. Pharmaceuticals7 (2022): 810.
8. Shamim H., et al. “Role of metformin in the management of polycystic ovarian syndrome-associated acne: A systematic review”. Cureus8 (2022): e28462.
9. AlSinan A and Shaman AA. “A study to measure the health awareness of polycystic ovarian syndrome in Saudi Arabia”. Global Journal of Health Sciences 8 (2017): 130.
10. Aljuaid A., et al. “Knowledge, attitude, and practice of lifestyle modifications among Saudi women diagnosed with polycystic ovary syndrome (PCOS)”. Cureus11 (2023): e49398.
11. Alruwaili G., et al. “General public awareness toward polycystic ovarian syndrome among females in Saudi Arabia”. International Journal of Medicine in Developing Countries 11 (2020): 1847-1853.
12. Jakhar R., et al. “Awareness of polycystic ovarian syndrome among college going females in Gurgaon: A cross-sectional study”. Annals of the National Academy of Medical Sciences 3 (2022): 149-156.
13. Haq N., et al. “Prevalence and knowledge of polycystic ovary syndrome (PCOS) among female science students of different public Universities of Quetta, Pakistan”. Imperial Journal of Interdisciplinary Research 6 (2017): 385-392.
14. Goh JE., et al. “Assessment of prevalence, knowledge of polycystic ovary syndrome and health-related practices among women in klang valley: A cross-sectional survey”. Frontiers in Endocrinology (Lausanne) 13 (2022): 985588.